View Post

Next-Generation COVID-19 Vaccines are Needed

In COVID-19, Latest News by Precision Vaccinations

Despite the availability of safe and effective vaccines, the SARS-CoV-2 coronavirus continues to circulate across the globe as 2022 comes to an end.
The existing COVID-19 vaccines have had a profoundly positive effect during the pandemic, reducing hospitalization and related fatalities.
Problems with vaccine hesitancy present throughout the pandemic continue today, wrote researchers with the US Food and Drug Administration and Brown University.

View Post

Cancer Prevention Vaccination Schedule Simplified

In COVID-19, Latest News by Precision Vaccinations

Parents concerned about their children's risk of being diagnosed with certain cancers have an important vaccination decision to make next year. Should they follow new guidance published by the World Health Organization (WHO)?
Or adhere to the U.S. Centers for Disease Control and Prevention (CDC) current multi-step human papovavirus (HPV) vaccination schedule?
As of February 2022, the CDC recommends two doses of the 9-valent HPV vaccine for all adolescents at age 11 or 12.

View Post

TSA Tips For Travelers With Disabilities

In Travel Vaccine News by Travel Vaccine

When departing from Texas on a winter holiday, air travelers with disabilities or medical conditions and who use medical devices should not think of a Transportation Security Administration (TSA) checkpoint as a barrier to their vacation.
While all travelers must undergo screening at the Austin-Bergstrom International Airport TSA checkpoint, passengers and companions may consult a TSA officer about the best way to relieve any concerns during the screening process.

View Post

First Monoclonal Antibody to Treat COVID-19 Approved

In COVID-19, Latest News by Precision Vaccinations

The first monoclonal antibody (mAbs) to treat COVID-19 has joined a short list of U.S. Food and Drug Administration (FDA) approved antivirals.
Roche announced yesterday that the FDA had approved Actemra® (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients receiving systemic corticosteroids and requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

View Post

First Approved Capsid Inhibitor-Based HIV Treatment Option

In COVID-19, Latest News by Precision Vaccinations

While the U.S. Food and Drug Administration (FDA) has yet to approve an HIV vaccine candidate, approvals have been granted for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.
Gilead Sciences, Inc. announced today that Sunlenca® (lenacapavir), in combination with other antiretrovirals, has been granted approval by the U.S. FDA for treating HIV-1 infection in HTE adults with MDR HIV-1 infection.
Sunlenca is now the first and only FDA Approved Capsid Inhibitor-Based HIV treatment option.